Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family

        Print
| Source: Orion
ORION CORPORATION STOCK EXCHANGE RELEASE 30 NOVEMBER 2012 at 1:10  PM  EET

Orion Corporation is developing a budesonide-formoterol formulation combining
budesonide as an anti-inflammatory agent and formoterol as a long-acting
bronchodilator to expand the range of the inhalable Easyhaler(®) drug product
family for treatment of asthma and COPD.

Based on the favorable pharmacokinetic study results of this Easyhaler-
development programme Orion is planning to apply for a marketing authorisation
for the combined budesonide-formoterol formulation. Orion currently estimates
that the marketing authorisation application would be submitted in Europe during
the first half of 2013.


Orion Corporation


 Timo Lappalainen  Olli Huotari
 President and CEO SVP, Corporate Functions


Contact persons:

Reijo Salonen, Senior Vice President, Research and Development (as of  Monday
3  December)
tel. +358 50 966 3647


Jari Karlson, CFO
tel. +358 50 966 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi




Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.

Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



[HUG#1661691]